References
- Armstrong LR, Preston EJ, Reichert M, Phillips DL, Nisenbaum R, Todd NW, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000; 31: 107–9
- Pasquale K, Wiatrack B, Woolley A, Lewis L. Microdebrider versus CO2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 2003; 113: 139–43
- Uloza V. The course of laryngeal papillomatosis treated by endolaryngeal microsurgery. Eur Arch Otorhinolaryngol 2000; 257: 498–501
- Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clercq E, et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J Med Virol 1998; 54: 219–25
- Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 1999; 125: 1143–8
- Peyton Shirley W, Wiatrak B. Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children?. Int J Pediatr Otorhinolaryngol 2004; 68: 413–18
- Food and Drug Administration. 1996 http://www.fda.gov/cder/foi/adcomm/96/avdac_joint_031496_summmin_ac.pdf.
- Pudszuhn A, Welzel C, Bloching M, Neumann K. Intralesional Cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Otorhinolaryngol 2007; 264: 63–70
- Wemer RD, Lee JH, Hoffman HT, Robinson RA, Smith RJ. Case of progressive dysplasia concomitant with intralesional Cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005; 114: 836–9
- Broekema FI, Dikkers FG. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2008; 265: 871–9
- Derkay CS, Malis DJ, Zalzal G, Wiatrack BJ, Kashima HK, Coltrera M. A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope 1998; 108: 935–7
- Naiman AN, Ayari S, Nicollas R, Landry G, Colombeau B, Froehlich P. Intermediate-term and long-term results after treatment by Cidofovir and excision in juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol 2006; 115: 667–72
- Buchinsky FJ, Donfack J, Derkay CS, Choi SS, Conley SF, Myer CM3rd, et al. Age of child, more than HPV type is associated with clinical course in recurrent respiratory papillomatosis. PloS ONE 2008; 3: e2263
- Wiatrack BJ, Wiatrack DW, Broker TR, Lewis L. Recurrent Respiratory Papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004; 114: 1–23
- Reeves WC, Ruparelia SS, Swanson KI, Derkay CS, Marcus A, Unger ER. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 976–82
- Hawkes M, Campisi P, Zafar R, Punthakee X, Dupuis A, Forte V, et al. Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Pediatr Infect Dis J 2008; 27: 149–53
- Rimell FL, Shoemaker DL, Pou AM, Jordan JA, Post JC, Ehrlich GD. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope 1997; 107: 915–18
- Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11-associatd recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001; 4: 68–72
- Gerein V. Prognosis factors of recurrent respiratory papillomatosis spread to lower airway passages. Int J Pediatr Otorhinolaryngol 2004; 68: 1589–90
- Reidy PM, Dedo HH, Rabah R, Field JB, Mathog RH, Gregoire L, et al. Integration of human papillomavirus type 11 in recurrent respiratory papilloma-associated cancer. Laryngoscope 2004; 114: 1906–9